Alnylam Pharmaceuticals Company Profile (NASDAQ:ALNY)

About Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals logoAlnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ALNY
  • CUSIP: 02043Q10
  • Web:
  • Market Cap: $7.47 billion
  • Outstanding Shares: 91,733,000
Average Prices:
  • 50 Day Moving Avg: $80.76
  • 200 Day Moving Avg: $63.14
  • 52 Week Range: $31.38 - $86.92
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -15.48
  • P/E Growth: -0.33
Sales & Book Value:
  • Annual Revenue: $66 million
  • Price / Sales: 113.17
  • Book Value: $12.25 per share
  • Price / Book: 6.65
  • EBIDTA: ($436,510,000.00)
  • Net Margins: -670.81%
  • Return on Equity: -45.53%
  • Return on Assets: -34.43%
  • Debt-to-Equity Ratio: 0.13%
  • Current Ratio: 8.84%
  • Quick Ratio: 8.84%
  • Average Volume: 945,894 shs.
  • Beta: 2.95
  • Short Ratio: 11.01

Frequently Asked Questions for Alnylam Pharmaceuticals (NASDAQ:ALNY)

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its earnings results on Wednesday, August, 9th. The company reported ($1.34) EPS for the quarter, missing the Zacks' consensus estimate of ($1.22) by $0.12. The firm earned $15.93 million during the quarter, compared to the consensus estimate of $23.86 million. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The firm's revenue was up 82.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.05) EPS. View Alnylam Pharmaceuticals' Earnings History.

Where is Alnylam Pharmaceuticals' stock going? Where will Alnylam Pharmaceuticals' stock price be in 2017?

18 analysts have issued twelve-month target prices for Alnylam Pharmaceuticals' stock. Their predictions range from $50.00 to $126.00. On average, they anticipate Alnylam Pharmaceuticals' share price to reach $83.44 in the next twelve months. View Analyst Ratings for Alnylam Pharmaceuticals.

What are analysts saying about Alnylam Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:

  • 1. Chardan Capital analysts commented, "We believe far and away the least likely scenario is that patisiran fails to demonstrate efficacy in APOLLO, considering that, as discussed above, the clinical effect of TTR silencing has been de- risked by top-line results from NEURO-TTR. A significant disconnect between the APOLLO and NEURO-TTR studies is, in our view, only possible if, as discussed in the 9 January 2017 company note, the differences in the patient population between the phase II OLE and APOLLO study (APOLLO has more advanced patients than the phase II OLE) leads to a slower rate of mNIS+7 increase in the placebo arm than is expected in natural history since, to our understanding, the NEURO-TTR patient population is likely somewhere between the phase II OLE and APOLLO populations." (8/10/2017)
  • 2. According to Zacks Investment Research, "Alnylam expects 2017 to be a pivotal year with its first phase III data read out from the APOLLO study for its late-stage pipeline candidate patisiran. It also plans to advance two additional programs into late-stage trials in 2017 and already commenced a phase III study for one of its candidates-fitusiran in July 2017. The company expects to achieve the profile of three marketed products by the end of 2020. Shares of the company have outperformed the Medical-Biomedical/Genetics industry year-to-date. The company’s RNAi technology has allowed it to ink collaborations with leading pharmaceutical and life sciences companies like Novartis, Roche, Monsanto and Sanofi. These deals not only provide it with funds but also take its RNAi technology outside the core focus area. However, the company’s dependence on collaborations for revenues is concerning." (7/17/2017)
  • 3. Needham & Company LLC analysts commented, "Alnylam reported additional results from Phase 2 OLE trial of fitusiran in Hemophilia A and B pts w/ and w/ o inhibitors. Efficacy w/ respect to Annualized Bleeding Rate and target antithrombin knockdown remains favorable and consistent w/ prior data from this program. Alnylam reported several asymptomatic >3X ALT elevations, one of which led to a discontinuation. Mgmt believes these events may be tied to HCV infection, highlighting that all events occurred in pts w/ history of HCV and most significant events were observed in pts w/ active infection. Alnylam is excluding Hemophilia pts w/ active HCV infection from Phase 3 trials. Data from Phase 1 trial published today are not consistent with a dose-dependent impact on ALT elevation. We continue to have a favorable view towards the program given current overall profile (safety, efficacy, and convenience), but acknowledge a level of risk around liver enzymes, which will probably not be clarified until Phase 3 completed." (7/10/2017)

Who are some of Alnylam Pharmaceuticals' key competitors?

Who are Alnylam Pharmaceuticals' key executives?

Alnylam Pharmaceuticals' management team includes the folowing people:

  • Michael W. Bonney, Independent Chairman of the Board
  • Barry E. Greene, President
  • John M. Maraganore Ph.D., Chief Executive Officer, Director
  • Manmeet S. Soni, Chief Financial Officer, Senior Vice President, Principal Financial Officer
  • Yvonne L. Greenstreet M.D., Chief Operating Officer, Executive Vice President
  • Akshay K. Vaishnaw M.D., Ph.D., Executive Vice President - Research and Development
  • Laurie B. Keating, Senior Vice President, General Counsel, Secretary
  • Pushkal Garg M.D., Senior Vice President - Clinical Development, Chief Medical Officer
  • Theresa Heggie, Senior Vice President, Head of Europe and Canada
  • Peter F. Smith Ph.D., Senior Vice President - Early Development

Who owns Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.92%), Dodge & Cox (10.66%), Vanguard Group Inc. (7.45%), BlackRock Inc. (6.02%), Baillie Gifford & Co. (3.98%) and State Street Corp (2.11%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, David E I Pyott, David-Alexandre C Gros, John Maraganore, Kevin P Starr, Laurie Keating, Michael Mason, Michael W Bonney, Philip A Sharp and Sanofi. View Institutional Ownership Trends for Alnylam Pharmaceuticals.

Who sold Alnylam Pharmaceuticals stock? Who is selling Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., State Street Corp, Dodge & Cox, Balyasny Asset Management LLC, Rockefeller Financial Services Inc., Wells Fargo & Company MN, Tekla Capital Management LLC and Pictet Asset Management Ltd.. Company insiders that have sold Alnylam Pharmaceuticals stock in the last year include Akshay Vaishnaw, Michael Mason and Philip A Sharp. View Insider Buying and Selling for Alnylam Pharmaceuticals.

Who bought Alnylam Pharmaceuticals stock? Who is buying Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Vanguard Group Inc., Janus Henderson Group PLC, BlackRock Inc., TIAA CREF Investment Management LLC, PDT Partners LLC, Farallon Capital Management LLC and Broadfin Capital LLC. Company insiders that have bought Alnylam Pharmaceuticals stock in the last two years include David E I Pyott, David-Alexandre C Gros, Laurie Keating, Michael W Bonney and Sanofi. View Insider Buying and Selling for Alnylam Pharmaceuticals.

How do I buy Alnylam Pharmaceuticals stock?

Shares of Alnylam Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alnylam Pharmaceuticals' stock price today?

One share of Alnylam Pharmaceuticals stock can currently be purchased for approximately $81.42.

MarketBeat Community Rating for Alnylam Pharmaceuticals (NASDAQ ALNY)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  616 (Vote Outperform)
Underperform Votes:  210 (Vote Underperform)
Total Votes:  826
MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 12 Buy Ratings
Consensus Rating:Buy (Score: 2.61)
Consensus Price Target: $83.44 (2.49% upside)

Analysts' Ratings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/11/2017Credit Suisse GroupReiterated RatingBuy$96.00LowView Rating Details
8/10/2017Stifel NicolausReiterated RatingBuy$47.00 -> $56.00MediumView Rating Details
8/10/2017Chardan CapitalReiterated RatingBuy$131.00 -> $124.00MediumView Rating Details
8/10/2017Morgan StanleyBoost Price TargetEqual Weight$46.00 -> $50.00MediumView Rating Details
8/10/2017Barclays PLCBoost Price TargetEqual Weight$50.00 -> $70.00HighView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageOutperform$99.00HighView Rating Details
7/17/2017Ladenburg Thalmann Financial ServicesSet Price TargetBuy -> Buy$80.00 -> $90.00LowView Rating Details
7/11/2017Cowen and CompanyReiterated RatingBuy$100.00LowView Rating Details
7/10/2017Needham & Company LLCReiterated RatingBuy$98.00LowView Rating Details
6/26/2017J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
6/22/2017Jefferies Group LLCReiterated RatingBuy -> Buy$102.00LowView Rating Details
6/21/2017Piper Jaffray CompaniesReiterated RatingOverweight$116.00 -> $126.00LowView Rating Details
6/2/2017Janney Montgomery ScottInitiated CoverageUnderperform -> Sell$69.70 -> $67.00LowView Rating Details
5/17/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$44.00 -> $64.00MediumView Rating Details
5/17/2017Leerink SwannReiterated RatingMarket Perform$53.00 -> $67.00HighView Rating Details
4/17/2017BMO Capital MarketsInitiated CoverageOutperform$73.00MediumView Rating Details
3/20/2017FBR & CoReiterated RatingBuyHighView Rating Details
2/3/2017JMP SecuritiesSet Price TargetBuy$69.00N/AView Rating Details
11/26/2015S&P Equity ResearchDowngradeBuy -> HoldN/AView Rating Details
(Data available from 8/18/2015 forward)


Earnings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Earnings by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Earnings History by Quarter for Alnylam Pharmaceuticals (NASDAQ ALNY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($1.22)($1.34)$23.86 million$15.93 millionViewListenView Earnings Details
5/5/2017Q1 2017($1.22)($1.25)$22.91 million$19.00 millionViewN/AView Earnings Details
2/8/2017Q416($1.34)($1.32)$10.66 million$17.50 millionViewListenView Earnings Details
11/2/2016Q316($1.14)($1.21)$9.14 million$13.70 millionViewN/AView Earnings Details
8/4/2016Q216($1.24)($1.05)$8.09 million$8.70 millionViewListenView Earnings Details
5/2/2016Q116($1.05)($1.21)$7.79 million$7.30 millionViewListenView Earnings Details
2/11/2016Q415($0.96)($1.07)$9.59 million$7.60 millionViewListenView Earnings Details
11/9/2015Q315($0.91)($0.91)$7.55 million$6.30 millionViewN/AView Earnings Details
8/6/2015Q215($0.75)($0.85)$12.64 million$8.69 millionViewN/AView Earnings Details
5/7/2015Q115($0.65)($0.62)$15.40 million$18.51 millionViewN/AView Earnings Details
2/12/2015Q414($0.66)($0.28)$13.10 million$24.00 millionViewN/AView Earnings Details
11/5/2014Q314($0.63)($0.58)$8.93 million$11.00 millionViewN/AView Earnings Details
8/7/2014Q214($0.54)($0.63)$9.36 million$7.30 millionViewN/AView Earnings Details
5/8/2014Q114($1.18)($0.39)$10.80 million$8.30 millionViewN/AView Earnings Details
2/19/2014Q413($0.45)($0.51)$9.98 million$10.80 millionViewN/AView Earnings Details
11/6/2013Q313($0.39)($0.48)$8.64 million$9.00 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.35)($0.29)$8.99 million$8.70 millionViewListenView Earnings Details
5/6/2013Q1 2013($0.29)($0.15)$15.56 million$18.60 millionViewListenView Earnings Details
2/7/2013Q4 2012($1.45)($1.20)$15.82 million$8.50 millionViewListenView Earnings Details
11/5/2012Q312($0.32)($0.31)$17.30 million$16.80 millionViewN/AView Earnings Details
8/6/2012($0.21)($0.25)ViewN/AView Earnings Details
5/3/2012($0.35)($0.25)ViewN/AView Earnings Details
2/9/2012($0.33)($0.33)ViewN/AView Earnings Details
11/1/2011($0.35)($0.31)ViewN/AView Earnings Details
8/1/2011($0.36)($0.33)ViewN/AView Earnings Details
5/2/2011($0.30)($0.38)ViewN/AView Earnings Details
2/17/2011($0.35)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)
2017 EPS Consensus Estimate: ($4.93)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.36)($1.30)($1.33)
Q2 20172($1.20)($1.15)($1.18)
Q3 20172($1.25)($1.18)($1.22)
Q4 20172($1.32)($1.10)($1.21)
(Data provided by Zacks Investment Research)


Dividend History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 88.99%
Insider Trades by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Insider Trades by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/31/2017SanofiMajor ShareholderBuy297,501$71.87$21,381,396.87View SEC Filing  
5/30/2017Laurie KeatingSVPBuy11,500$65.35$751,525.00View SEC Filing  
5/23/2017Akshay VaishnawEVPSell11,000$75.00$825,000.00View SEC Filing  
5/16/2017Michael MasonVPSell9,375$70.00$656,250.00View SEC Filing  
5/15/2017Akshay VaishnawSVPSell43,750$65.00$2,843,750.00View SEC Filing  
1/25/2017Philip A SharpDirectorSell15,000$37.95$569,250.00View SEC Filing  
1/18/2017Philip A SharpDirectorSell15,000$37.83$567,450.00View SEC Filing  
11/30/2016Akshay VaishnawCMOSell29,165$44.99$1,312,133.35View SEC Filing  
10/13/2016David E I PyottDirectorBuy27,900$37.00$1,032,300.00View SEC Filing  
7/20/2016John MaraganoreCEOSell30,151$64.69$1,950,468.19View SEC Filing  
4/20/2016John MaraganoreCEOSell30,151$67.46$2,033,986.46View SEC Filing  
3/9/2016Michael W BonneyDirectorBuy2,000$58.36$116,720.00View SEC Filing  
2/22/2016David-Alexandre C GrosSVPBuy1,000$62.75$62,750.00View SEC Filing  
2/1/2016SanofiMajor ShareholderBuy205,030$69.75$14,300,842.50View SEC Filing  
1/20/2016John MaraganoreCEOSell30,152$71.78$2,164,310.56View SEC Filing  
12/4/2015Philip A. SharpDirectorSell30,000$109.00$3,270,000.00View SEC Filing  
12/2/2015John MaraganoreCEOSell58,689$104.87$6,154,715.43View SEC Filing  
11/20/2015John MaraganoreCEOSell58,690$102.88$6,038,027.20View SEC Filing  
11/12/2015Kevin P. StarrDirectorSell75,000$103.89$7,791,750.00View SEC Filing  
6/16/2015Akshay VaishnawCMOSell8,750$128.83$1,127,262.50View SEC Filing  
5/12/2015Michael W BonneyDirectorBuy2,000$112.16$224,320.00View SEC Filing  
4/21/2015Paul SchimmelDirectorSell10,000$130.02$1,300,200.00View SEC Filing  
3/19/2015Dennis A AusielloDirectorSell5,000$120.00$600,000.00View SEC Filing  
3/17/2015Akshay VaishnawCMOSell8,750$116.86$1,022,525.00View SEC Filing  
1/29/2015SanofiMajor ShareholderBuy97,118$95.00$9,226,210.00View SEC Filing  
1/26/2015John MaraganoreCEOBuy10,000$95.00$950,000.00View SEC Filing  
1/26/2015Steven M PaulDirectorBuy1,000$95.00$95,000.00View SEC Filing  
12/19/2014Barry E GreeneCOOSell11,200$100.00$1,120,000.00View SEC Filing  
12/16/2014Akshay VaishnawEVPSell10,626$93.60$994,593.60View SEC Filing  
12/15/2014Michael MasonVPSell22,162$97.50$2,160,795.00View SEC Filing  
11/18/2014Laurence ReidSVPSell10,000$90.67$906,700.00View SEC Filing  
11/17/2014Barry E GreeneCOOSell33,200$89.63$2,975,716.00View SEC Filing  
10/28/2014Paul SchimmelDirectorSell15,000$95.00$1,425,000.00View SEC Filing  
10/22/2014Dennis A AusielloDirectorSell5,000$90.00$450,000.00View SEC Filing  
10/13/2014Philip A SharpDirectorSell110,000$85.00$9,350,000.00View SEC Filing  
9/25/2014Kevin P StarrDirectorSell90,000$78.09$7,028,100.00View SEC Filing  
9/24/2014Kevin P StarrDirectorSell45,000$79.08$3,558,600.00View SEC Filing  
9/18/2014John MaraganoreCEOSell113,668$77.71$8,833,140.28View SEC Filing  
9/16/2014Akshay VaishnawEVPSell10,625$72.04$765,425.00View SEC Filing  
8/18/2014Laurence ReidSVPSell13,500$67.34$909,090.00View SEC Filing  
6/26/2014John MaraganoreCEOSell113,668$65.45$7,439,570.60View SEC Filing  
6/17/2014Akshay VaishnawEVPSell10,625$69.82$741,837.50View SEC Filing  
5/21/2014John ClarkeDirectorSell35,000$53.80$1,883,000.00View SEC Filing  
5/19/2014Laurence ReidSVPSell13,500$57.83$780,705.00View SEC Filing  
5/15/2014John MaraganoreCEOSell113,668$56.73$6,448,385.64View SEC Filing  
3/25/2014Sanofimajor shareholderBuy344,448$66.88$23,036,682.24View SEC Filing  
3/18/2014Akshay VaishnawEVPSell32,769$73.95$2,423,267.55View SEC Filing  
2/19/2014Laurence ReidSVPSell20,400$80.06$1,633,224.00View SEC Filing  
1/24/2014Akshay VaishnawEVPSell7,890$85.75$676,567.50View SEC Filing  
1/13/2014Paul SchimmelDirectorSell15,000$85.36$1,280,400.00View SEC Filing  
12/20/2013Paul SchimmelDirectorSell15,000$65.00$975,000.00View SEC Filing  
12/17/2013Akshay VaishnawEVPSell33,480$60.72$2,032,905.60View SEC Filing  
10/22/2013Paul SchimmelDirectorSell15,000$60.00$900,000.00View SEC Filing  
9/11/2013John MaraganoreCEOSell58,947$55.50$3,271,558.50View SEC Filing  
9/10/2013Akshay VaishnawEVPSell6,250$57.48$359,250.00View SEC Filing  
8/14/2013John MaraganoreCEOSell60,000$48.97$2,938,200.00View SEC Filing  
7/12/2013Michael MasonVPSell14,200$50.00$710,000.00View SEC Filing  
7/10/2013John MaraganoreCEOSell60,000$37.11$2,226,600.00View SEC Filing  
7/1/2013Michael MasonVPSell27,000$32.00$864,000.00View SEC Filing  
6/17/2013Michael MasonVPSell23,625$29.93$707,096.25View SEC Filing  
6/11/2013Akshay VaishnawEVPSell15,000$31.08$466,200.00View SEC Filing  
5/28/2013Barry E GreeneCOOSell22,822$30.00$684,660.00View SEC Filing  
5/28/2013Laurence ReidSVPSell5,000$30.00$150,000.00View SEC Filing  
3/26/2013Kevin P StarrDirectorSell52,631$23.49$1,236,302.19View SEC Filing  
1/22/2013Philip A SharpDirectorBuy4,967$20.13$99,985.71View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Latest Headlines for Alnylam Pharmaceuticals (NASDAQ:ALNY)
DateHeadline logoOrbimed Advisors Llc Buys Cigna Corp, Clovis Oncology Inc, Gilead Sciences Inc, Sells Centene ... - August 18 at 3:53 PM logoAlnylam Pharmaceuticals, Inc. 2017 Q2 - Results - Earnings Call Slides - August 18 at 3:52 PM logoBidaskClub Downgrades Alnylam Pharmaceuticals, Inc. (ALNY) to Buy - August 17 at 12:08 AM logoMerck CEO quits presidential council after Charlottesville violence ‘as a matter of personal conscience,’ and Trump attacks him - August 15 at 4:47 PM logoAlnylam Shoots For The Moon With Apollo - Seeking Alpha - August 14 at 4:05 PM logoAlnylam Pharmaceuticals, Inc. Earnings: Waiting for Apollo - August 14 at 2:55 PM logoAlnylam Pharmaceuticals, Inc. to Post Q3 2017 Earnings of ($1.18) Per Share, Leerink Swann Forecasts (NASDAQ:ALNY) - August 14 at 3:52 AM logoAlnylam Pharmaceuticals, Inc. (ALNY) Rating Reiterated by Credit Suisse Group - August 12 at 5:42 PM logoAlnylam (ALNY) Q2 Loss Narrower than Expected, Sales Miss - Nasdaq - August 12 at 3:34 PM logoEARNINGS SUMMARY: Details of Alnylam Pharmaceuticals Inc. Q2 Earnings Report - August 11 at 4:11 PM logoIonis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs - August 11 at 4:11 PM logoSee what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. - August 11 at 4:11 PM logoAlnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALNY-US : August 11, 2017 - August 11 at 4:11 PM logoAlnylam (ALNY) Q2 Loss Narrower than Expected, Sales Miss - August 10 at 10:13 PM logoAlnylam Pharmaceuticals' (NASDAQ:ALNY) "Buy" Rating Reiterated at Chardan Capital - August 10 at 7:02 PM logoAlnylam Pharmaceuticals (ALNY) Q2 2017 Results - Earnings Call Transcript - Seeking Alpha - August 10 at 5:10 PM logoEdited Transcript of ALNY earnings conference call or presentation 9-Aug-17 8:30pm GMT - August 10 at 5:10 PM logoAlnylam Pharmaceuticals' (ALNY) Buy Rating Reiterated at Stifel Nicolaus - August 10 at 5:02 PM logoAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Price Target Raised to $0.00 at Barclays PLC - August 10 at 3:03 PM logoAfter 10 months, Alnylam still can't explain patient trial deaths - August 10 at 1:59 AM logoAlnylam Pharmaceuticals, Inc. (ALNY) Issues Quarterly Earnings Results - August 10 at 12:50 AM logoAlnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity - Business Wire (press release) - August 9 at 8:59 PM logoAlnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity - August 9 at 8:58 PM logoAlnylam reports 2Q loss - August 9 at 8:58 PM logoWhy Alnylam Pharmaceuticals (ALNY) Might Surprise This Earnings Season - Nasdaq - August 8 at 8:25 PM logoAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Recommendation of "Buy" by Analysts - August 8 at 7:04 PM logoWhy Alnylam Pharmaceuticals (ALNY) Might Surprise This Earnings Season - August 8 at 3:21 PM logoArena Pharmaceuticals (ARNA) Q2 Loss Wider than Expected - August 8 at 3:21 PM logo3 Drug Stocks Poised to Surpass Estimates in Q2 Earnings - August 8 at 3:21 PM logoEndo (ENDP) Beats Q2 Earnings & Sales, 2017 Guidance Lowered - August 8 at 3:21 PM logoZoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View - August 8 at 3:21 PM logoLeerink Swann Comments on Alnylam Pharmaceuticals, Inc.'s Q2 2017 Earnings (NASDAQ:ALNY) - August 7 at 7:04 AM logoZacks: Analysts Anticipate Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Will Post Quarterly Sales of $22.22 Million - August 6 at 7:14 AM logoAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Upgraded to Strong-Buy at BidaskClub - August 5 at 9:56 PM logoZacks: Brokerages Expect Alnylam Pharmaceuticals, Inc. (ALNY) Will Announce Earnings of -$1.20 Per Share - August 4 at 8:26 PM logoAlnylam Pharmaceuticals (ALNY) Update On Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary TransthyretinMediated (hATTR) - August 4 at 4:08 PM logoAlnylam to Webcast Conference Call Discussing Second Quarter 2017 Financial Results - Business Wire (press release) - August 1 at 9:47 PM logoAlnylam to Webcast Conference Call Discussing Second Quarter 2017 Financial Results - August 1 at 4:46 PM logoAlnylam to Host Fourth Annual “RNAi Roundtable” Webcast Series - July 27 at 3:21 PM logoSomerville Kurt F Buys JM Smucker Co, Analog Devices Inc, Fortive Corp, Sells NXP ... - Nasdaq - July 26 at 3:53 PM logoAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to Release Quarterly Earnings on Wednesday - July 26 at 7:14 AM logoALNY Crosses Above Average Analyst Target - July 21 at 5:23 PM logoAlnylam Pharmaceuticals, Inc. (ALNY) Lowered to "Hold" at Zacks Investment Research - July 17 at 4:04 PM logoZacks: Brokerages Expect Alnylam Pharmaceuticals, Inc. (ALNY) Will Announce Quarterly Sales of $22.22 Million - July 15 at 8:19 AM logoAlnylam Pharmaceuticals, Inc. (ALNY) Receives Average Recommendation of "Buy" from Analysts - July 14 at 6:44 PM logo-$1.20 Earnings Per Share Expected for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) This Quarter - July 13 at 2:16 PM logoAlnylam (ALNY) Upgraded to Buy on Solid Pipeline Growth - July 12 at 9:19 PM logoAlnylam Pharmaceuticals (ALNY) & Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study - Presentation - July 11 at 9:59 PM logoAlnylam Buckles Down On A Belt Of Rare Diseases - Seeking Alpha - July 11 at 4:59 PM logoToday's Research Reports on Stocks to Watch: Alnylam Pharmaceuticals and Hemispherx Biopharma - July 11 at 4:59 PM



Alnylam Pharmaceuticals (ALNY) Chart for Friday, August, 18, 2017

This page was last updated on 8/18/2017 by Staff